UNSPSC 51262505: Guanazodine sulfate

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H20N4.H2O.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKI3DAO4S6. The term guanazodine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule guanazodine sulfate under HS 29339990 and SITC 51577. SMILES: C1CCCNC(CC1)CNC(=N)N.OS(=O)(=O)O.

UNSPSC 51262505 Guanazodine sulfate is a Commodity code that in recent state and local procurement activity maps to pharmaceutical products and pharmacy benefit services, though recent opportunities show a mismatch with the abstract code name. The two recent postings tagged to this code involve naloxone procurement and direct-to-manufacturer prescription programs — neither involves guanazodine sulfate specifically. State and local governments using this code tag are buying pharmaceutical inventory (naloxone, drug deactivation systems) and exploring pharmacy benefit program redesign. Issuing bodies include county health departments and state health and human services agencies.

Seminole County, Florida posted IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program that would bypass pharmacy benefit managers and group purchasing organizations. The code shows sparse recent activity and limited geographic representation — only Florida and Texas appear in the posted opportunities. The guanazodine sulfate code itself does not appear to be a primary pharmaceutical procurement driver in state and local markets; the mismatch between the code name and recent solicitations suggests this code may not reflect current state and local spending patterns in pharmaceutical procurement, and business development effort should be grounded in direct visibility of actual health agency RFPs and RFQs rather than reliance on this code classification.